Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.
Edison Investment Research - Pharmaceutical & healthcare - Pluristem Therapeutics: Edison Investment Research is terminating coverage on Pluristem Therapeutics (PSTI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. ISIN: US72940R1023
AELIX Therapeutics and Gilead Sciences have entered a joint clinical research collaboration for the analysis of proprietary investigational products. Called AELIX-003,...Read More... The post AELIX Therapeutics and Gilead Sciences to trial HIV therapy appeared first on Drug Development Technology.
US-based Gilead Sciences has formed a strategic alliance with Tango Therapeutics for the discovery, development and commercialisation of new targeted...Read More... The post Gilead partners with Tango Therapeutics to develop new cancer drugs appeared first on Pharmaceutical Technology.
ADC Therapeutics has dosed the first patient in a Phase II clinical trial to examine the efficacy and safety of...Read More... The post ADC Therapeutics doses first patient in Phase II trial of ADCT-402 appeared first on Drug Development Technology.
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and u...
Novo Nordisk has entered into research collaboration with UK-based E-therapeutics for the development of new treatment strategies for a specific...Read More... The post Novo Nordisk and e-therapeutics alliance to focus on type-2 diabetes appeared first on Pharmaceutical Technology.
InvaGen Pharmaceuticals, a unit of India-based Cipla, has signed definitive agreements to buy US-based specialty pharmaceutical firm Avenue Therapeutics for...Read More... The post InvaGen to acquire Avenue Therapeutics for $215m appeared first on Pharmaceutical Technology.
Athenex (NASDAQ:ATNX) has announced that Axis Therapeutics has entered into an MOU with the Kong Kong Polytechnic University to explore the establishment of a joint research center to advance the application of immunotherapy in Kong Kong. As quoted in the press release: Axis Therapeutics, a newly established joint venture to be owned as 55% by … Continued The post Athenex Announces Axis Ther...
Cara Therapeutics has started dosing patients in the KALM-2 trial, a Phase lll pivotal study of KORSUVA (CR845/difelikefalin) injection to...Read More... The post Cara Therapeutics starts dosing in KALM-2 trial appeared first on Drug Development Technology.
Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in...Read More... The post Roche subsidiary Genentech to acquire Jecure Therapeutics appeared first on Pharmaceutical Technology.
Massachusetts-based Skyhawk Therapeutics is closing out the month of June with some positive news that will carry over through the near future.
LNC Therapeutics (developing therapies for obesity and related cardiometabolic diseases) raised €6.5mm ($7.7mm) in its Seri...
DUBLIN–(BUSINESS WIRE)–The “Global CNS Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The Global CNS therapeutics market to grow at a CAGR of 4.36% during the period 2018-2022. Global CNS Therapeutics Market 2018-2022, has been prepared based on … Continue reading → Cet article
FDA alerted Mylan to expect a complete response letter related to its ANDA for generic Advair. The company said it...
Collectively, CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) lost nearly $500 million in value in a single day.
US-based gene therapy company Spark Therapeutics has reported $25.2m in revenue, $80.2m in net income and $2.15 basic income per...Read More... The post Spark Therapeutics Q2 financial results: income growth helped by US launch of Luxturna appeared first on Pharmaceutical Technology.
Amicus Therapeutics has entered a collaboration with the Perelman School of Medicine at the University of Pennsylvania to develop new...Read More... The post Deals this week: Amicus Therapeutics, Janssen Pharmaceuticals, Ionis Pharmaceuticals appeared first on Pharmaceutical Technology.
UK-based biotech company KaNDy Therapeutics has reported positive results from the Phase Ib/IIa RELENT-1 clinical trial of NT-814 to treat...Read More... The post KaNDy Therapeutics reports positive data in RELENT-1 study appeared first on Drug Development Technology.
Biotechnology company United Therapeutics has signed a licensing deal worth up to $1.2bn with biopharmaceutical firm Arena Pharmaceuticals for a...Read More... The post United Therapeutics reaches $1.2bn licensing deal with Arena appeared first on Pharmaceutical Technology.
Millendo Therapeutics has begun a Phase llb clinical trial to investigate the efficacy and safety of nevanimibe for the treatment...Read More... The post Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH appeared first on Drug Development Technology.
Axsome Therapeutics has enrolled the first patient in the Assessing Clinical Episodes in Depression (ASCEND) trial of AXS-05 to treat...Read More... The post Axsome Therapeutics enrols first patient in ASCEND trial appeared first on Drug Development Technology.
Roche has acquired UK-based immuno-oncology company Tusk Therapeutics in a deal valued at up to €655m ($759m). As per the...Read More... The post Roche acquires Tusk Therapeutics in up to $759m deal appeared first on Pharmaceutical Technology.
Sorrento Therapeutics announced on Monday that its subsidiary, Scilex Pharmaceuticals, received US$140 million in funding for a pain medication. The post Sorrento Therapeutics Subsidiary Scilex Receives New Funding appeared first on Investing News Network.
US-based Sage Therapeutics has reported an integrated analysis of three clinical trials that investigated its brexanolone injection for the treatment...Read More... The post Sage Therapeutics reports integrated trial data for brexanolone appeared first on Drug Development Technology.
Concurrent with Roche’s acquisition of Tusk Therapeutics Ltd., Tusk spun out a new company called Black Belt Therapeutics t...